Published in J Am Acad Dermatol on July 01, 1999
The Goeckerman regimen for the treatment of moderate to severe psoriasis. J Vis Exp (2013) 0.87
Cost-of-illness in psoriasis: comparing inpatient and outpatient therapy. PLoS One (2013) 0.77
The Patient's Guide to Psoriasis Treatment. Part 4: Goeckerman Therapy. Dermatol Ther (Heidelb) (2016) 0.75
Psoriasis remission time at the Dead Sea. J Am Acad Dermatol (2000) 0.75
Topical Therapies in Psoriasis. Indian Dermatol Online J (2017) 0.75
The impact of psoriasis on quality of life: results of a 1998 National Psoriasis Foundation patient-membership survey. Arch Dermatol (2001) 3.92
Sterility of refrigerated injectable collagen syringes after injection of patient. J Am Acad Dermatol (1992) 2.05
Finasteride in the treatment of men with frontal male pattern hair loss. J Am Acad Dermatol (1999) 1.67
Pustular and erythrodermic psoriasis complicated by acute respiratory distress syndrome. Arch Dermatol (1997) 1.48
Proceedings of the Psoriasis Combination and Rotation Therapy Conference. Deer Valley, Utah, Oct. 7-9, 1994. J Am Acad Dermatol (1996) 1.45
New cutaneous manifestations of systemic diseases. Am Fam Physician (1995) 1.42
Effect of UV-B phototherapy on plasma HIV type 1 RNA viral level: a self-controlled prospective study. Arch Dermatol (1998) 1.40
A 500-kb region on chromosome 16p13.1 contains the pseudoxanthoma elasticum locus: high-resolution mapping and genomic structure. J Mol Med (Berl) (2000) 1.39
Methotrexate in psoriasis: consensus conference. J Am Acad Dermatol (1998) 1.39
Atopic dermatitis. Lancet (1998) 1.37
Long-term safety of ustekinumab in patients with moderate-to-severe psoriasis: final results from 5 years of follow-up. Br J Dermatol (2013) 1.26
Cellular differentiation and expression of matrix genes in type 1 neurofibromatosis. Lab Invest (1988) 1.19
Two considerations for patients with psoriasis and their clinicians: what defines mild, moderate, and severe psoriasis? What constitutes a clinically significant improvement when treating psoriasis? J Am Acad Dermatol (2000) 1.12
Effects of administration of a single dose of a humanized monoclonal antibody to CD11a on the immunobiology and clinical activity of psoriasis. J Am Acad Dermatol (2000) 1.11
Metastatic Crohn's disease. J Am Acad Dermatol (1984) 1.07
Diagnosis of pseudoxanthoma elasticum by scar biopsy in patients without characteristic skin lesions. N Engl J Med (1987) 1.07
Induction of 8-oxo-7,8-dihydro-2'-deoxyguanosine by ultraviolet radiation in calf thymus DNA and HeLa cells. Photochem Photobiol (1997) 1.06
Altered expression of angiopoietins and Tie2 endothelium receptor in psoriasis. J Invest Dermatol (2001) 1.05
Pseudoxanthoma elasticum: significance of limited phenotypic expression in parents of affected offspring. J Am Acad Dermatol (2001) 1.05
Identification of possible reactive oxygen species involved in ultraviolet radiation-induced oxidative DNA damage. Free Radic Biol Med (1997) 1.00
Cardiovascular safety of ustekinumab in patients with moderate to severe psoriasis: results of integrated analyses of data from phase II and III clinical studies. Br J Dermatol (2011) 1.00
Benzo[a]pyrene enhances the formation of 8-hydroxy-2'-deoxyguanosine by ultraviolet A radiation in calf thymus DNA and human epidermoid carcinoma cells. Biochemistry (1998) 0.98
Anti-CD4 monoclonal antibody treatment of moderate to severe psoriasis vulgaris: results of a pilot, multicenter, multiple-dose, placebo-controlled study. J Am Acad Dermatol (2000) 0.97
Assessment and management of methotrexate hepatotoxicity in psoriasis patients: report from a consensus conference to evaluate current practice and identify key questions toward optimizing methotrexate use in the clinic. J Eur Acad Dermatol Venereol (2010) 0.97
DNA structural integrity and base composition affect ultraviolet light-induced oxidative DNA damage. Biochemistry (1998) 0.96
Collagen alterations in chronically sun-damaged human skin. Photochem Photobiol (1993) 0.95
Scavenging of hydrogen peroxide and inhibition of ultraviolet light-induced oxidative DNA damage by aqueous extracts from green and black teas. Free Radic Biol Med (1999) 0.95
Calcification of elastic fibers in pseudoxanthoma elasticum. Mt Sinai J Med (1996) 0.93
Subcutaneous fat necrosis of the newborn with hypercalcemia. J Am Acad Dermatol (1987) 0.91
Isoflavone genistein inhibits the initiation and promotion of two-stage skin carcinogenesis in mice. Carcinogenesis (1998) 0.90
Elastin gene deletions in Williams syndrome patients result in altered deposition of elastic fibers in skin and a subclinical dermal phenotype. Pediatr Dermatol (2000) 0.90
Ultraviolet radiation increases tropoelastin accumulation by a post-transcriptional mechanism in dermal fibroblasts. J Invest Dermatol (1995) 0.90
Inhibition of ultraviolet B (UVB)-induced c-fos and c-jun expression in vivo by a tyrosine kinase inhibitor genistein. Carcinogenesis (1998) 0.89
Effectiveness of norgestimate and ethinyl estradiol in treating moderate acne vulgaris. J Am Acad Dermatol (1997) 0.89
Nerve growth factor receptors on dissociated neurofibroma Schwann-like cells. Cancer Res (1986) 0.89
Cutaneous mycobacteriosis: occurrence and significance in two patients with the acquired immunodeficiency syndrome. Arch Dermatol (1987) 0.89
Hypopigmented variant of mycosis fungoides: demography, histopathology, and treatment of seven cases. J Am Acad Dermatol (1995) 0.89
Basement membrane proteins, interstitial collagens, and fibronectin in neurofibroma. J Invest Dermatol (1985) 0.88
Differential regulation of P53 and Bcl-2 expression by ultraviolet A and B. J Invest Dermatol (1998) 0.86
Kaposi's sarcoma and acquired immunodeficiency syndrome. Postmortem findings in twenty-four cases. J Am Acad Dermatol (1987) 0.84
Consensus workshop on the toxic effects of long-term PUVA therapy. Arch Dermatol (1998) 0.84
Acanthosis Nigricans, insulin action, and hyperandrogenism: clinical, histological, and biochemical findings. J Clin Endocrinol Metab (1991) 0.84
Combination therapy with vitamin D analogues. Br J Dermatol (2001) 0.83
Tamoxifen reduces endogenous and UV light-induced oxidative damage to DNA, lipid and protein in vitro and in vivo. Carcinogenesis (1998) 0.83
Topical corticosteroids in psoriasis: strategies for improving safety. J Eur Acad Dermatol Venereol (2009) 0.81
Pseudoxanthoma elasticum and calcinosis cutis. J Am Acad Dermatol (2000) 0.81
The efficacy of metronidazole 1% cream once daily compared with metronidazole 1% cream twice daily and their vehicles in rosacea: a double-blind clinical trial. J Am Acad Dermatol (1998) 0.81
Peristomal pyoderma gangrenosum. J Am Acad Dermatol (1992) 0.81
Acne therapy: clinical pearls. Semin Cutan Med Surg (2001) 0.80
Pemphigus vulgaris after initiation of psoralen and UVA therapy for psoriasis. J Am Acad Dermatol (1994) 0.80
The use of alefacept in the treatment of psoriasis. Skin Therapy Lett (2003) 0.80
Photoinduced dermal pigmentation in patients taking tricyclic antidepressants: histology, electron microscopy, and energy dispersive spectroscopy. J Am Acad Dermatol (1999) 0.80
Physician perceptions and experience of current treatment in actinic keratosis. J Eur Acad Dermatol Venereol (2014) 0.80
Multiple hamartoma syndrome. J Am Acad Dermatol (1987) 0.80
Treatment of verrucae vulgaris with alpha 2 interferon. J Infect Dis (1986) 0.80
Determination of desmosines in elastin-related skin disorders by isocratic high-performance liquid chromatography. Exp Mol Pathol (1990) 0.79
Compatibility of calcipotriene with other topical medications. J Am Acad Dermatol (1998) 0.79
Cutaneous reactions to vitamin K1 injections. J Am Acad Dermatol (1993) 0.79
Association between acrochordons and colonic polyps. J Am Acad Dermatol (1986) 0.79
PUVA (8-methoxy-psoralen plus ultraviolet A) induces the formation of 8-hydroxy-2'-deoxyguanosine and DNA fragmentation in calf thymus DNA and human epidermoid carcinoma cells. Free Radic Biol Med (1999) 0.79
Association of Pityrosporum orbiculare (Malassezia furfur) with seborrheic dermatitis in patients with acquired immunodeficiency syndrome (AIDS). J Am Acad Dermatol (1989) 0.79
Factors impacting the combination of topical corticosteroid therapies for psoriasis: perspectives from the International Psoriasis Council. J Eur Acad Dermatol Venereol (2011) 0.79
Acquired ichthyosis and hyperparathyroidism. J Am Acad Dermatol (1989) 0.79
Presence of type I and VI collagen mRNAs in endothelial cells in cutaneous neurofibromas. Lab Invest (1991) 0.79
Alefacept in the treatment of psoriasis in patients for whom conventional therapies are inadequate. Dermatology (2005) 0.79
Abnormalities of fibrillin in acquired cutis laxa. J Am Acad Dermatol (1994) 0.78
Tinea versicolor treated with terbinafine 1% solution. Int J Dermatol (1999) 0.78
Cutaneous manifestations of inflammatory bowel disease. J Eur Acad Dermatol Venereol (2000) 0.78
Elastase digestion of normal and pseudoxanthoma elasticum lesional skin elastins. Exp Mol Pathol (1991) 0.78
Interactions between tazarotene and ultraviolet light. J Am Acad Dermatol (1999) 0.77
Advances in psoriasis therapy. Adv Dermatol (1997) 0.77
Topical calcipotriene in combination with UVB phototherapy for psoriasis. Int J Dermatol (1997) 0.77
The cost of psoriasis treatment. J Eur Acad Dermatol Venereol (2001) 0.77
A double-blind, vehicle-controlled study of clobetasol propionate 0.05% (Temovate) scalp application in the treatment of moderate to severe scalp psoriasis. J Am Acad Dermatol (1991) 0.77
Psoriasis. Drugs Today (Barc) (1998) 0.76
Retrospective study of the efficacy of narrowband UVB and acitretin. J Dermatolog Treat (2003) 0.76
From the literature: intralesional 5-FU in the treatment of hypertrophic scars and keloids: clinical experience. J Am Acad Dermatol (2000) 0.76
In vitro compatibility of tazarotene with other topical treatments of psoriasis. J Am Acad Dermatol (2000) 0.76
Psoriasis and Crohn's disease. Mt Sinai J Med (1999) 0.76
Improving the safety profile of long-term PUVA therapy. J Am Acad Dermatol (1999) 0.75
Retrospective analysis of the treatment of psoriasis of the palms and soles. J Dermatolog Treat (2003) 0.75
Cost-effectiveness of methotrexate and Goeckerman therapy: a flawed analysis. Arch Dermatol (1999) 0.75
Generalized morphea. Mt Sinai J Med (1998) 0.75
Immunofluorescence and electron microscopic findings in a congenital arrector pili hamartoma. Am J Dermatopathol (1989) 0.75
Addition of short-contact anthralin therapy to an ultraviolet B phototherapy regimen: assessment of efficacy. J Am Acad Dermatol (1985) 0.75
Calcipotriene ointment applied once a day for psoriasis: a double-blind, multicenter, placebo-controlled study. Arch Dermatol (1996) 0.75
Dermatologic manifestations of systemic disease. Clin Podiatr Med Surg (1998) 0.75
Comparison of urinary 8-hydroxy-2'-deoxyguanosine in patients treated with topical corticosteroids, UV-B, and psoralen UV-A therapies. Arch Dermatol (2000) 0.75
Pseudoxanthoma elasticum and pregnancy. Cutis (1996) 0.75
Transition from methotrexate and cyclosporine to other therapies including retinoids, ultraviolet light and biologic agents in the management of patients with psoriasis. J Dermatolog Treat (2003) 0.75
Case 2-1995. From the weekly grand rounds of the Department of Dermatology at the Mount Sinai Hospital. Mt Sinai J Med (1995) 0.75
Clinical pearl: vitamin E (alpha-tocopherol), 800 IU daily, may reduce retinoid toxicity. J Am Acad Dermatol (1999) 0.75
Genital lentigines in a 6-year-old boy with a family history of Cowden's disease: clinical and genetic evidence of the linkage between Bannayan-Riley-Ruvacalba syndrome and Cowden's disease. J Cutan Med Surg (2001) 0.75
The penetration of 0.005% fluticasone propionate ointment in eyelid skin. J Am Acad Dermatol (2001) 0.75
Reactive perforating collagenosis. Mt Sinai J Med (1998) 0.75
Lyme disease. Mt Sinai J Med (1997) 0.75
Extramammary Paget's disease. Mt Sinai J Med (2000) 0.75
Pyoderma gangrenosum associated with anticardiolipin antibodies in a pregnant patient. Int J Dermatol (1997) 0.75
Topical antipsoriatics. Skin Therapy Lett (2000) 0.75
The case for micrographically controlled skin surgery. J Am Acad Dermatol (2000) 0.75